Clinical and prognostic factors for melanoma of the skin using SEER registries: Collaborative stage data collection system, version 1 and version 2

Cancer

Volumn 120, Issue S23, 2014, Pages 3807-3814

  Kosary, Carol L ^a   Altekruse, Sean F ^a   Ruhl, Jennifer ^a   Lee, Richard ^b   Dickie, Lois ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Cancer staging; Cutaneous; Melanoma; Skin

Indexed keywords

LACTATE DEHYDROGENASE;

ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CUTANEOUS MELANOMA; DISTANT METASTASIS; HUMAN; LYMPH NODE METASTASIS; MELANOMA; RISK FACTOR; TUMOR INVASION; CHOROID TUMOR; COHORT ANALYSIS; CONJUNCTIVA TUMOR; EYE TUMOR; HEAD AND NECK TUMOR; IRIS TUMOR; LYMPH NODE; PATHOLOGY; REGISTER; RETROSPECTIVE STUDY; SKIN TUMOR; TRENDS;

CHOROID NEOPLASMS; COHORT STUDIES; CONJUNCTIVAL NEOPLASMS; EYE NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; IRIS NEOPLASMS; LYMPH NODES; MELANOMA; NEOPLASM STAGING; REGISTRIES; RETROSPECTIVE STUDIES; SEER PROGRAM; SKIN NEOPLASMS;

EID: 84911936335     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29050     Document Type: Article

References (30)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL; Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. American Joint Committee on Cancer. Chicago: Springer-Verlag; 2010.
2. National Cancer Institute. Genetics of Skin Cancer (PDQ). Available at: http://www.cancer.gov/cancertopics/pdq/genetics/skin/HealthProfessional/page4/. Accessed October 18, 2013.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
4. Howlader N, Noone, AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2010. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed October 18, 2013.
5. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG. AJCC Cancer Staging Manual. 6th ed. American Joint Committee on Cancer. Chicago: Springer-Verlag; 2002.
6. Fritz A, Jack A, Parkin DM, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva,Switzerland: World Health Organization; 2000.
7. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: 6199-6206.
8. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134.
9. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449-458.
10. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426-433.
11. Busam KJ. The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma. Ann Surg Oncol. 2004; 11:360-361.
12. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35: 433-444.
13. Scolyer RA, Mihm MC, Cochran AJ. Pathology of melanoma. In: Balch CM, Houghton AN, Sober AJ, et al, eds. Cutaneous Melanoma. St. Louis, MO:Quality Medical Publishing; 2009;205-250.
14. Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol. 2005;29:305-317.
15. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med. 2006;355:1370-1371.
16. Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009;60: 872-875.
17. Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (> or54-mm) melanoma: should we be doing it? Ann Surg Oncol. 2003;10:408-415.
18. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7:469-474.
19. Dessureault S, Soong SJ, Ross MI, et al. Improved staging of nodenegative patients with intermediate to thick melanomas (> 1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001;8:766-770.
20. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9:637-645.
21. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
22. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
23. Rousseau DL, Ross MI, Johnson WW, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569-574.
24. Allen AC, Spitz S. Malignant melanoma: Aclinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1-45.
25. Tompkins VN. Cutaneous melanoma: ulceration as a prognostic sign. Cancer. 1953;6:1215-1218.
26. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-149; quiz 182-184.
27. In't Hout FE, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, Scolyer RA. Prognostic importance of the extent of ulceration on patients with clinically localized cutaneous melanoma. Ann Surg. 2012;255:1165-1170.
28. Urso, C. Are growth phases exclusive to cutaneous melanoma? J Clin Pathol. 2004;57:560.
29. Guerry D, Synnestvedt M, Elder DE, Schultz D. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Derm. 1993; 100:342S-345S.
30. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.